Research Article | OPEN ACCESS
Anti-hepatocarcinoma Effects of a Food Additive Resveratrol Nanosuspension Against Human HepG2 Cells
1, 3Shi-Qiong Luo, 2Wen-Liang Lu, 3Yi-Fei Wang and 1, 4Zhi-Ping Wang
1Hospital of Jinan University, Guangzhou 510632, China
2Tianjin Tasly Institute, Tianjin 300410; School of Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 300193, China
3Institute of Biological Medicine, Jinan University, Guangzhou 510632, China
4School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, China
Advance Journal of Food Science and Technology 2015 3:210-213
Received: December 10, 2014 | Accepted: January 8, 2015 | Published: May 15, 2015
Abstract
Hepatocarcinoma, a malignant cancer, threaten human life badly. It is a current issue to seek the effective natural remedy from plant to treat cancer due to the resistance of the advanced hepatocarcinoma to chemotherapy. Resveratrol (Res), a major symbol ingredient in red grapes and peanuts, has a wide range of pharmacological properties and is considered to have anti-hepatocarcinoma effects. However its low oral bioavailability restricts its wide application. In this report, Res-nanosuspension (Res-NS) composed of Res and poloxamer 188 was prepared by high pressure homogenization technique. The in vitro anti-hepatocarcinoma effects of Res-NS relative to efficacy of bulk Res were evaluated. The particle size and zeta potential of Res-NS were 159.4 nm and -2.1 mV, respectively. MTT assay showed that Res-NS effectively inhibited the proliferation of HepG2 cells and the corresponding IC50 values of Res-NS and bulk Res were 2.91 and 7.13 &mu g/mL. These results suggest that the delivery of Res-NS is a promising approach for treating tumors.
Keywords:
Antitumor activity, cytotoxicity, HepG2 cells, nanosuspension, resveratrol,
References
-
Amiot, M.J., B. Romier, T.M. Anh Dao, R. Fanciullino, J. Ciccolini, R. Burcelin, L. Pechere, C. Emond, J.F. Savouret and E. Seree, 2013. Optimization of trans-Resveratrol bioavailability for human therapy. Biochimie, 95(6): 1233-1238.
CrossRef PMid:23376875
-
Aras, A., A.R. Khokhar, M.Z. Qureshi, M.F. Silva, A. Sobczak-Kupiec, E.A. Pineda, A.A. Hechenleitner and A.A. Farooqi, 2014. Targeting cancer with nano-bullets: Curcumin, EGCG, resveratrol and quercetin on flying carpets. Asian Pac. J. Cancer P., 15(9): 3865-3871.
CrossRef PMid:24935565
-
Athar, M., J.H. Back, X.W. Tang, K.H. Kim, L. Kopelovich, D.R. Bickers and A.L. Kim, 2007. Resveratrol: A review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharm., 224(3): 274-283.
CrossRef PMid:17306316 PMCid:PMC2083123
-
Bishayee, A., T. Politis and A.S. Darvesh, 2010. Resveratrol in the chemoprevention and treatment of hepatocellular carcinoma. Cancer Treat. Rev., 36(1): 43.
CrossRef PMid:19910122
-
Carter, L.G., J.A. D'Orazio and K.J. Pearson, 2014. Resveratrol and cancer: a focus on in vivo evidence. Endocr. Relat. Cancer, 21: R209-R221.
CrossRef PMid:24500760 PMCid:PMC4013237
-
Chong, J., A. Poutaraud and P. Hugueney, 2009. Metabolism and roles of stilbenes in plants. Plant Sci., 177(3): 143-55.
CrossRef
-
Deng, X.K., W. Yin, W.D. Li, F.Z. Yin, X.Y. Lu and X.C. Zhang, 2006. The anti-tumor effects of alkaloids from the seeds of Strychnos nux-vomica on HepG2 cells and its possible mechanism. J. Ethnopharmacol., 106: 179-186.
CrossRef PMid:16442763
-
Franciosoa, A., P. Mastromarino, A. Masci, M. d'Erme and L. Mosca, 2014. Chemistry, stability and bioavailability of resveratrol. Med. Chem., 10(3): 237-245.
CrossRef
-
Gao, L., G.Y. Liu, J.L. Ma, X.Q. Wang, L. Zhou, X. Li and F. Wang, 2013. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs. Pharm. Res., 30: 307-324.
CrossRef PMid:23073665
-
Hiroto, Y., K. Tadokoro, T. Tsuda, E. Nakazono, K. Ohnaka, R. Takayanagi, N. Hamasaki and H. Tsuda, 2011. Resveratrol, a phytoestrogen found in red wine, down-regulates protein S expression in HepG2 cells. Thromb. Res., 127(1): e1-7.
CrossRef PMid:20926118
-
Karadag, A., B. Ozcelik and Q.R. Huang, 2014. Quercetin nanosuspensions produced by high-pressure homogenization. J. Agr. Food Chem., 62: 1852-1859.
CrossRef PMid:24471519 -
Liang, M., S.C. Li, B. Shen, J.P. Cai, C. Li, Z.Y. Wang, X.G. Li, J. Gao, H.Y. Huang, X.Y. Zhang and J.Y. Li, 2012. Anti-hepatocarcinoma effects of aconitum coreanum polysaccharides. Carbohyd. Polym., 88: 973-976.
CrossRef
-
Liversidge, G.G. and K.C. Cundy, 1995. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: I. Absolute oral bioavailability of nanocrystalline danazol in beagle dogs. Int. J. Pharm., 125: 91-97.
CrossRef
-
Pandita, D., S. Kumar, N. Poonia and V. Lather, 2014. Solid lipid nanoparticles enhance oral bioavailability of resveratrol, a natural polyphenol. Food Res. Int., 62: 1165-1174.
CrossRef
-
Parkin, D.M., 2001. Global cancer statistics in the year 2000. Lancet Oncol., 2: 533-543.
CrossRef
-
Rajasekaran, D., J. Elavarasan, M. Sivalingam, E. Ganapathy, A. Kumar, K. Kalpana and D. Sakthisekaran, 2011. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Mol. Med. Rep., 4(6): 1211-1217.
PMid:21850372
-
Renaud, S. and M. de Lorgeril, 1992. Wine, alcohol, platelets and the French paradox for coronary heart disease. Lancet, 339(8808): 1523-1529.
CrossRef
-
Sales, J.M. and A.V. Resurreccion, 2014. Resveratrol in peanuts. Crit. Rev. Food Sci. Nutr., 54(6): 734-770.
CrossRef PMid:24345046
-
Schuster, S., M. Penke, T. Gorski, S. Petzold-Quinque, G. Damm, R. Gebhardt, W. Kiess and A. Garten, 2014. Resveratrol differentially regulates NAMPT and SIRT1 in hepatocarcinoma cells and primary human hepatocytes. PLoS One, 9(3): e91045.
CrossRef PMid:24603648 PMCid:PMC3946349
-
Sessa, M., M.L. Balestrieri, G. Ferrari, L. Servillo, D. Castaldo, N. D'Onofrio, F. Donsė and R. Tsao, 2014. Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems. Food Chem., 147: 42-50.
CrossRef PMid:24206683
-
Sinclair, D.A. and J.A. Baur, 2006. Therapeutic potential of resveratrol: The in vivo evidence. Nat. Rev. Drug Discov., 5(6): 493-506.
CrossRef PMid:16732220
-
Thomas, M.B. and A.X. Zhu, 2005. Hepatocellular carcinoma: The need for progress. J. Clin. Oncol., 23: 2892-2899.
CrossRef PMid:15860847
-
Weng, C.J., C.F. Wu, H.W. Huang, C.H. Wu, C.T. Ho and G.C. Yen, 2010. Evaluation of anti-invasion effect of resveratrol and related methoxy analogues on human hepatocarcinoma cells. J. Agr. Food Chem., 58(5): 2886-2894.
CrossRef PMid:20131808
-
Zhang, D.R., T.W. Tan, L. Gao, W. Zhao and P. Wang, 2007. Preparation of azithromycin nanosuspensions by high pressure homogenization and its physicochemical characteristics studies. Drug Dev. Ind. Pharm., 33: 569-575.
CrossRef PMid:17520449
-
Zhang, H. and R. Yang, 2014. Resveratrol inhibits VEGF gene expression and proliferation of hepatocarcinoma cells. Hepato-gastroenterol., 61(130): 410-412.
Competing interests
The authors have no competing interests.
Open Access Policy
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Copyright
The authors have no competing interests.
|
|
![](http://www.maxwellsci.com/images/AJFST-maxw.jpg) |
ISSN (Online): 2042-4876
ISSN (Print): 2042-4868 |
![Submit Manuscript](../images/sub.jpg) |
Information |
|
|
|
Sales & Services |
|
|
|